Long-Term Follow-Up, Quality of Life, and Survival of Patients with Lambert-Eaton Myasthenic Syndrome
Neurol 94:e511-e520, Lipka, A.F.,et al, 2020
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Paraneoplastic Syndromes Involving the Nervous System
NEJM 349:1543-1554, Darnell,R.B. &Posner,J.B., 2003
A Randomized Trial of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Neurol 54:603-607, Sanders,D.B.,et al, 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Neurologic Emergencies in Cancer Patients
Neurol Clin 16:1-37, Schiff,D.,et al, 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Effects of Intravenous Immunoglobulin on Muscle Weakness & Calcium-Channel Autoantibodies in Lambert-Eaton Myasthenic Synd
Neurol 47:678-683, Bain,P.G.,et al, 1996
Lambert-Eaton Myasthenic Syndrome Presenting with Severe Respiratory Failure
Muscle & Nerve 19:1328-1333996., Nicolle,M.W.,et al, 1996
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Reversal of Subacute Paraneoplastic Cerebellar Syndrome with Intravenous Immunoglobulin
Neurol 44:1184-1185, Counsell,C.E.,et al, 1994
Clinical and Electrophysiologic Improvement in Lambert-Eaton Syndrome with Intravenous Immunoglobulin Therapy
Neurol 42:1422-1423, Bird,S.J., 1992
Response of the Lambert-Eaton Myasthenic Syndrome to Treatment of Associated Small-Cell Lung Carcinoma
Neurol 40:1552-1556, Chalk,C.H.,et al, 1990
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
3, 4-Diaminopyridine in the Treatment of Lambert-Eaton Myasthenic Syndrome
NEJM 321:1567-1571, 1607-16081989., McEvoy,K.M.,et al, 1989
The Lambert-Eaton Myasthenic Syndrome, A Review of 50 Cases
Brain 111, 577-5961988., O'Neill,J.H.,et al, 1988
The Eaton-Lambert (Myasthenic) Syndrome in Association with Systemic Lupus Erythematosus
Arch Neurol 43:1186-1187, Hughes,R.L.&Katirji,M.B., 1986
Plasma Exchange & Immunosuppressive Drug Treatment in the Lambert-Eaton Myasthenic Syndrome
Neurol 34:480-485, Newsom-Davis,J.,et al, 1984
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Plasmapheresis & Immunosuppressive Drug Therapy in the Eaton-Lambert Syndrome
Ann Neurol 11:570-575, Da,P.C.,et al, 1982
Eaton-Lambert Myasthenic Syndrome:Long-term Treatment of Three Patients with Prednisone
Ann Neurol 10:448-453, Streib,E.W.,et al, 1981
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Clinical Syndromes of Myasthenia in Infancy & Childhood
Arch Neurol 35:97, Fenichel,G.M., 1978
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977
Myasthenia Gravis Assoc. with Wasp Sting
JAMA 235:2120, Brumlik,J., 1976
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975